Pharvaris B.V. (PHVS) Stock Forecast & Price Target

Pharvaris is a promising biopharmaceutical company with a novel, oral bradykinin B2 receptor antagonist, deucrictibant, in late-stage development for the treatment and prevention of HAE attacks. With upcoming pivotal Phase 3 data in both on-demand and prophylactic settings, positive open-label extension studies, and a potential expansion into the AAE-C1INH market, Pharvaris has a strong and diverse pipeline. This, coupled with its strong cash position and impressive data from its presentations at ACAAI 2025, make Pharvaris a potentially successful player in the competitive market of HAE treatments.

Pharvaris is facing potential regulatory hurdles in gaining approval for their novel drug and may have to conduct additional or longer studies, limiting their ability to gain traction in the market. The company has a relatively healthy cash runway through the launch of their on-demand drug, but it remains uncertain if the drug will have the same level of efficacy as injectable therapies like Takhzyro. However, if the results of their upcoming CHAPTER-3 study show a similar degree of efficacy, it could put deucrictibant in a competitive position. Ultimately, the success of deucrictibant and Pharvaris' stock will depend on the results of their upcoming trials and the ability to gain approval from regulators.